A new advance may make it possible to use off-the-shelf CAR T cells provided by healthy donors. The new approach studied in mice equipped CAR T cells with the viral protein Nef.

Researchers found that bioengineered CAR-T cells when mixed with other immune cells can "donate" proteins, suggesting ...

VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy ...

Penn Medicine is one of the first institutions to develop FDA-approved CAR T-cell therapies. This therapy is currently ...

CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a patient's own immune T cells and engineering them to recognize specific targets ...

The second CAR-T cell therapy, Qartemi, has been approved by India's drug regulator. Qartemi is a "living drug" for blood ...

Qartemi is a 'living drug' that has been approved by the Central Drugs Standard Control Organisation (CDSCO) for blood cancer ...

Therapy will cost Rs 35 to 50 lakh. India sees around 1.20 lakh new blood cancer cases and over 70,000 deaths annually from ...

Company prepares to advance to Phase 2 clinical trial in early 2025HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an ...

Immuneel Therapeutics launches affordable CAR-T therapy Qartemi for B-cell Non-Hodgkin Lymphoma, aiming to revolutionize ...